Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company is planning to commence a randomized clinical trial using psilocybin. This trial will be the broadest study of its kind, and the research will not have an upper limit, and will even include patients that have endured dozens of unsuccessful medical trials, including ketamine and electroconvulsive therapy.
McIntyre also telling Proactive, the study will demonstrate that the Company can effectively conduct a randomized controlled trial using psychedelic-assisted therapy and will allow the company to build s foundation for future studies.